E
PCVX icon

Ergoteles’s Vaxcyte PCVX Stock Holding History

Ergoteles’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,811
Closed -$305K – 1536
2021
Q4 		$305K Buy
+12,811
New +$298K 0.01% 845

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Ergoteles's PCVX Position: Q1 2022 in Review

Ergoteles sold out of Vaxcyte (PCVX) in Q1 2022, closing a stake of 12,811 shares — an estimated $305K sold.

Ergoteles first reported a position in PCVX in Q4 2021 and held it in 1 quarter. The position peaked at $305K in Q4 2021. 88 funds tracked by Wall St. Rank hold PCVX as of Q1 2022.

  • Ergoteles reported no remaining Vaxcyte position as of Q1 2022 after selling out during the quarter.
  • Ergoteles sold 12,811 Vaxcyte shares in Q1 2022, an estimated $305K.
  • Ergoteles first reported a position in Vaxcyte in Q4 2021 and held it in 1 quarter.
  • Ergoteles's Vaxcyte position peaked at $305K in Q4 2021.
  • 88 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2022.

Based on Ergoteles's 13F filing for Q1 2022, filed 13 May 2022.